Early research (Phase 1)Study completedNCT00000884
What this trial is testing
Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 84